Featured Research

from universities, journals, and other organizations

Considerably more patients may benefit from effective antidiabetic drug, study suggests

Date:
September 17, 2012
Source:
University of Gothenburg
Summary:
The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high. A new study has found that the risks have been substantially overrated. As a result, many more patients with diabetes may be able to enjoy the benefits of the medication.

The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high. A study at Sahlgrenska Academy, University of Gothenburg, Sweden, has found that the risks have been substantially overrated. As a result, many more patients with diabetes may be able to enjoy the benefits of the medication.

Type 2 diabetes, a very common condition, is increasingly prevalent around the world. Keeping diabetes under control and preventing complications requires not only lifestyle changes, but drug therapy to reduce blood glucose levels.

Among the most effective and frequently prescribed antidiabetics is metformin, which has been shown in a number of studies to lower the risk of death from cardiovascular disease. Because the drug has been considered causing an increased risk of developing a rare but life-threatening adverse effect known as lactic acidosis, it is not prescribed for patients with reduced kidney function.

Researchers at Sahlgrenska Academy, University of Gothenburg and Uppsala University have conducted a study involving 51,700 patients with type 2 diabetes from the Swedish national diabetes register and found that the risks are exaggerated.

The Gothenburg study shows that metformin is more effective than other glucose lowering drugs when it comes to reducing the risk of cardiovascular disease, serious infection and death in patients with normal kidney function, but also in patients with mild kidney impairment.

"Furthermore, patients with mild to moderate kidney impairment do not run an elevated risk of adverse effects from metformin,"says Nils Ekstrφm, a researcher at Sahlgrenska Academy. "Thus, the drug can be prescribed for many more patients with diabetes than is currently the case."

According to Nils Ekstrφm, a number of other countries already recommend metformin for patients with mild kidney impairment. "It is important to keep in mind that the results are for patients with mild to moderate kidney impairment," he says. "Metformin still cannot be recommended for patients with severe kidney impairment and should be prescribed with great caution for those patients. During periods of acute illness with dehydration, metformin should never be used."


Story Source:

The above story is based on materials provided by University of Gothenburg. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. Ekstrom, L. Schioler, A.-M. Svensson, K. Eeg-Olofsson, J. Miao Jonasson, B. Zethelius, J. Cederholm, B. Eliasson, S. Gudbjornsdottir. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open, 2012; 2 (4): e001076 DOI: 10.1136/bmjopen-2012-001076

Cite This Page:

University of Gothenburg. "Considerably more patients may benefit from effective antidiabetic drug, study suggests." ScienceDaily. ScienceDaily, 17 September 2012. <www.sciencedaily.com/releases/2012/09/120917090016.htm>.
University of Gothenburg. (2012, September 17). Considerably more patients may benefit from effective antidiabetic drug, study suggests. ScienceDaily. Retrieved September 1, 2014 from www.sciencedaily.com/releases/2012/09/120917090016.htm
University of Gothenburg. "Considerably more patients may benefit from effective antidiabetic drug, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/09/120917090016.htm (accessed September 1, 2014).

Share This




More Health & Medicine News

Monday, September 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) — Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) — A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) — Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) — California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins